Skip to content

Study · In vitro (cells) · 2019

2 results

Pharmacology of the giant panda (Ailuropoda melanoleuca) melanocortin-3 receptor.

Zhang HJ, Xie HJ, Wang W, Wang ZQ, Tao YX

General and comparative endocrinology1 Nov 2018Cited by 7 (Europe PMC)

PMID30391243 (opens in a new tab)DOI10.1016/j.ygcen.2018.10.024 (opens in a new tab)PepBankPUB-30391243
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In a receptor assay, giant panda MC3R bound NDP-MSH and D-Trp8-gamma-MSH with the highest affinity, in the same rank order as human MC3R.

    In plain wordsIn lab tests, the giant panda melanocortin-3 receptor bound NDP-MSH very strongly, in the same pattern as the human receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableBinding affinity of NDP-MSH for giant panda MC3R
    Study

    n: not reported in source

    Giant panda MC3R (amMC3R) with human MC3R as control
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that amMC3R bound NDP- and D-Trp8-γ-MSH with the highest affinity, followed by α-, β-, and γ-MSH, with the same rank order as hMC3R.
    1 context sentence
    Summary · context
    Using human MC3R (hMC3R) as a control, the binding of five agonists, [Nle4, D-Phe7]-α-melanocyte stimulating hormone (NDP-MSH), α-, β-, γ-, and D-Trp8-γ-MSH, was investigated, as well as Gs-cAMP and pERK1/2 signaling.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In cells expressing giant panda MC3R, pooled melanocortin agonists (including NDP-MSH) increased intracellular cAMP and activated pERK1/2.

    In plain wordsIn cells, a group of melanocortin agonists that included NDP-MSH raised cAMP and switched on pERK1/2 signaling through the panda receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasecAMP and pERK1/2 signaling after agonist stimulation
    Study

    n: not reported in source

    Giant panda MC3R (amMC3R) with human MC3R as control
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    When stimulated with agonists, amMC3R displayed increased intracellular cAMP and activation of pERK1/2.
    1 context sentence
    Summary · context
    Using human MC3R (hMC3R) as a control, the binding of five agonists, [Nle4, D-Phe7]-α-melanocyte stimulating hormone (NDP-MSH), α-, β-, γ-, and D-Trp8-γ-MSH, was investigated, as well as Gs-cAMP and pERK1/2 signaling.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.